Summit Therapeutics plc, the Oxford based drug discovery and development company advancing therapies for rare and infectious diseases, announced today that it has raised £15 million.

The Placing, which was oversubscribed, was conducted by means of an accelerated bookbuild with existing and new investors.

The funds will be used primarily to accelerate preparatory activities for a placebo controlled clinical trial of ezutromid, and for a potential regulatory filing of ezutromid in Duchenne muscular dystrophy (“DMD”) based on the 48-week results from the ongoing Phase 2 clinical trial called PhaseOut DMD

Singer Capital Markets acted as joint broker in relation to the Placing.

Ticker: SUMM
Website: www.summitplc.com

For further information please contact enquiry@n1singer.com